Free Republic

A new study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk disease. "We asked, can we deliver radiation safely and effectively in less time so that our high-risk patients can finish their treatment faster?" said Dr. Niazi. "Hypofractionated treatment for prostate cancer decreases financial toxicity to patients, and it is completed in 25 days instead of the usual 38 to 40 days. That's three...

The co-host of Bernie & Sid in the Morning, Bernard McGuirk passed away Wednesday night following a bout with prostate cancer, just a few weeks shy of his 65th birthday. McGuirk had been co-host of WABC’s Bernie & Sid in the Morning with Sid Rosenberg since April of 2018. A special tribute for McGuirk, including memories and thoughts from the WABC staff, will air on Tuesday, October 11, 2022. Red Apple CEO John Catsimatidis said, “We are all devastated by the loss of Bernie. He was a true New Yorker whose talent and intelligence propelled him to the top of...

Legendary New York City radio host Bernard McGuirk has died at the age of 64 following a “courageous” battle with prostate cancer, his station announced Thursday. McGuirk — who hosted WABC’s “Bernie & Sid in the Morning” with co-host Sid Rosenberg — died Wednesday night surrounded by family at a local hospital, the station said. He had been on the air in the city since 1986 and was the executive producer of the nationally syndicated program “Imus in the Morning.” In 2007, McGuirk moved to WABC with Don Imus, the late radio icon, and his “personality from day one dramatically...

Researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer. "We defined a potential strategy for both responders and nonresponders of the drug that may help men overcome resistance and prolong survival," says Liewei Wang, M.D., Ph.D. Dr. Wang explains that while several drug choices are available to control disease progression, many questions remain over which drugs to use in individual cases. Also, predictive biomarkers for drug resistance and sensitivity remain primarily unknown. Abiraterone acetate is a standard treatment option for men with castration-resistant prostate cancer. However,...

In men who have had prostate cancer surgery, urinary incontinence is a common side effect. Its frequency varies from one surgeon to the next. In a major study, the number of surgeries performed by the urology surgeon made no difference to the patients' incontinence risk. This surprised researchers. Prostate cancer is the most common form of cancer in men, with some 10,000 new cases detected annually in Sweden. If the tumor has not spread, the prostate gland is often operated on, usually with a robot-assisted, laparoscopic technique. Immediately after the procedure, almost all men are incontinent, because of disturbed activity...

A new study published by researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer. The lab study led by Luksana Chaiswing, Ph.D., is the first to demonstrate that betamethasone protects normal prostate cells from injury induced by radiation therapy, while making the cancer cells more susceptible to the treatment. Prostate cancer is the second leading cause of cancer deaths among men in the U.S. While radiation therapy is important to control the growth of prostate cancer, it presents a significant risk of increasing unwanted side effects, including injury...

Hormone therapy for prostate cancer increases the risk of cardiovascular disease-related death especially in older men, according to a population study involving more than 13,000 patients. The highest risk was for coronary heart disease and stroke. The increased risks were apparent from the second year after cancer diagnosis and were more pronounced in older men. "Hormone therapy is often used for patients with prostate cancer," says lead author Justinas Jonusas. "Our results suggest clinicians should consider risk reduction and mitigation strategies for cardiovascular disease when developing a treatment plan for men diagnosed with prostate cancer, particularly for older patients." The...

Researchers have found a significant difference in the gut microbiota of men with prostate cancer, compared with those who have benign biopsies. Although the finding is an association, it could partly explain the relationship between lifestyle effects and geographical differences in prostate cancer. Gut microbiota are the collection of microbes in the gastrointestinal tract and they affect processes and mechanisms in the body. The state of gut microbiota has been linked to many conditions, even in organs that are far from the intestines, but their role in prostate cancer is not understood. Professor Peter Bostrom used samples collected from patients...

William Hurt, the Oscar-winning actor who starred in films like Body Heat, The Big Chill and Broadcast News, has died at the age of 71. Hurt’s son Will confirmed his father’s death in a statement Sunday. “It is with great sadness that the Hurt family mourns the passing of William Hurt, beloved father and Oscar winning actor, on March 13, 2022, one week before his 72nd birthday,” the family said. “He died peacefully, among family, of natural causes. The family requests privacy at this time.

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. Standard treatment for patients with metastatic, hormone-sensitive prostate cancer includes the addition of either the chemotherapy drug docetaxel or an androgen-receptor pathway inhibitor to androgen-deprivation therapy, with the latter two treatments acting to lower the effects of androgen hormones, such as testosterone. Clinical trials that have combined all three treatments have generated conflicting results. To provide clarity, investigators designed...

Prostate cancer is the leading cause of cancer in men worldwide, and radiotherapy is one of the common forms of treatment. Researchers show that there is consistent improvement in overall survival in men with intermediate- and high-risk prostate cancer with the addition of hormone therapy to radiotherapy treatments. "Our research team set out to conduct a first-of-its-kind, comprehensive analysis by collecting individual patient data from each and every randomized trial conducted around the world, and performed a meta-analysis of the impact of various treatment intensification strategies using hormone therapy with radiation therapy for localized prostate cancer," said Daniel E. Spratt,...

Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading, could halve the risk of death from the disease. The researchers suggest that hormone therapy using abiraterone with prednisolone, could significantly reduce prostate cancer deaths and improve outcomes for thousands of people every year. Using abiraterone for this group of people is now being considered for use in NHS England based on this research. If successful, it could be rolled out to patients immediately. The study, published today in The Lancet, is part of the STAMPEDE trial and was led...

Nearly 80% of men with metastatic prostate cancer died from their malignancy, according to a retrospective cohort study. The findings fill an information gap because, remarkably, "data are lacking" on causes of death among men whose prostate cancer has spread to other sites, say lead author Ahmed Elmehrath, MD. "It was an important realization by our team that prostate cancer was the cause of death in 78% of patients," said senior author Omar Alhalabi, MD, of University of Texas MD Anderson Cancer Center, Houston, in an email to Medscape Medical News. The findings represent the near opposite of a commonly...

Men who get the COVID-19 vaccinations are being warned by a urologist in Palm Beach County, Florida, that they may cause a spike in the results on one medical test.It's Dr. Diego Rubinowicz who said, in a report by CBS12, that it is the PSA levels for men who are being tested, often routinely, for prostate cancer, that are affected.The report explained prostate cancer is a common cancer for men, with a quarter of a million cases or thereabouts diagnosed in 2021.But the doctor said he's been seeing elevated PSA test levels in men who got vaccinations, not necessarily related...

Abstract Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. Here, we demonstrate in a murine prostate cancer model, that high-fat diet (HFD) enhances the MYC transcriptional program through metabolic alterations that favour histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading to increased cellular proliferation and tumour burden. Saturated fat intake (SFI) is also associated with an enhanced MYC transcriptional signature in prostate cancer patients. The SFI-induced MYC signature independently predicts prostate...

If you own a dog, you already know they are masters of sniffing rears. Despite wielding powerful noses that can detect diabetes and even COVID-19, they often prioritize diving into the nearest posterior to make friends as opposed to putting them to good use, but you can’t stop them doing what they love. Steering them in the right direction, researchers from Medical Detection Dogs have concluded a trial for scent dogs detecting the presence of prostate cancer and found they are highly sensitive to the most aggressive forms of the disease. The study, which is published in the journal PLOS...

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment...

John Tesh vividly remembers the day he contemplated ending his own life. It was 2015, and the Emmy Award-winning journalist and popular radio host had been diagnosed with a rare form of prostate cancer and given just 18 months to live. “It was an incredibly painful experience,” Tesh, 63, recalled in an interview with The Christian Post. “I had complications from my first surgery where the opioids they gave me paralyzed my bowels and so my body was shutting down. One day, I looked at my wife with tears in my eyes and said, ‘You have to kill me.’” “They...

Scientists are reporting promising results from a year-long study where soundwaves were used to heat and destroy prostate cancers decade3d/Depositphotos View 2 Images Treating prostate cancer through traditional means such as surgery or radiotherapy carries certain risks, with some patients experiencing impotence, urinary problems and bowel trouble, among other unwanted side effects. Safer and less invasive treatment options could soon be on the table, however, including a novel MRI-guided ultrasound technique that eliminated significant cancers in 80 percent of subjects in a year-long study. The new technique is called MRI-guided transurethral ultrasound ablation (TULSA) and has been under development for...

A combination of enzalutamide and androgen deprivation therapy (ADT) significantly reduced the risk of metastatic progression or death over time in men with advanced prostate cancer, according to the results of clinical trial led by Duke Cancer Institute. The study enrolled 1,150 men with metastatic prostate cancer who had just begun treatment with androgen deprivation therapy or recently completed treatment with docetaxel and ADT; half of the men were randomly assigned to receive the combination therapy; half received ADT and a placebo. Most of the men, 62 percent, had high volume disease, defined as having more than four metastatic sites...